
Revelation Biosciences Announces Strategic Shift to Accelerate Gemini Development for Acute Kidney Injury, Targeting Phase 2a Data in 2027
Revelation Biosciences, a clinical-stage life sciences company focused on developing innovative therapies designed to restore balance to the body’s inflammatory response, has announced a strategic shift aimed at accelerating the development of Gemini, its proprietary therapeutic candidate targeting inflammatory pathways. Under the revised development strategy, the company plans to advance a streamlined Phase 2a clinical study in patients with stage 2 or stage 3 acute kidney injury (AKI). The approach is intended to generate important safety and efficacy data more quickly and at a substantially lower cost than the company’s previously planned development program.
Alongside the clinical development initiative, Revelation intends to explore strategic partnerships, licensing agreements and other business development opportunities with biotechnology and pharmaceutical companies. These activities are expected to support Gemini’s continued clinical advancement while expanding its potential commercial opportunities across acute and chronic inflammatory conditions.
The revised strategy reflects the company’s focus on generating meaningful clinical evidence with a more capital-efficient approach. By reducing the anticipated cost and complexity of the next clinical study, Revelation aims to obtain additional information about Gemini’s therapeutic potential and strengthen its position in discussions with prospective pharmaceutical partners.
Acute kidney injury represents a significant healthcare challenge, particularly among critically ill patients. The condition is characterized by a sudden decline in kidney function and can develop following severe infections, major surgery, cardiovascular complications, medication-related kidney damage and other serious medical conditions.
AKI affects approximately 50% of patients admitted to intensive care units and can progress to kidney failure or death in severe cases. Dialysis remains one of the principal treatment approaches for patients with severe AKI, while mortality rates exceed 50% in certain critically ill patient populations.
Despite the considerable clinical and economic burden associated with the condition, there are currently no approved pharmacological therapies that directly address the underlying inflammatory processes contributing to kidney injury. This unmet medical need creates an opportunity for innovative therapeutic approaches that target inflammation and potentially support kidney recovery.
Independent market research cited by Revelation estimates that approximately 2.3 million patients in the United States develop stage 2 or stage 3 AKI annually. The company estimates that this patient population represents a total addressable market of approximately $94 billion.
James Rolke, chairman and chief executive officer of Revelation Biosciences, highlighted Gemini’s potential to regulate inflammation through multiple biological pathways and its possible importance in treating acute kidney injury.
According to Rolke, the company’s revised strategy is designed to generate meaningful clinical data sooner while requiring substantially less capital. He also noted that the approach is intended to position Gemini for potential strategic partnerships that could support its continued development.
Gemini Targets Multiple Inflammatory Pathways
Gemini is Revelation Biosciences’ proprietary therapeutic candidate designed to restore the body’s natural inflammatory balance through a differentiated mechanism of action.
Inflammation is an essential biological response that helps the body defend against infections, tissue damage and other harmful stimuli. However, excessive or prolonged inflammatory activity can contribute to tissue injury, organ dysfunction and disease progression.
In acute kidney injury, inflammatory processes can play an important role in worsening kidney damage. The activation of inflammatory pathways can contribute to cellular injury and disrupt normal kidney function, potentially creating a cycle in which inflammation and tissue damage reinforce one another.
Gemini is being developed to address these processes by regulating the body’s inflammatory response rather than broadly suppressing inflammation.
The therapeutic candidate is designed to activate the TRIF signaling pathway and modulate multiple inflammatory activities. Through this approach, Gemini aims to influence several biological processes involved in inflammation and tissue damage.
By targeting multiple pathways, the treatment is intended to interrupt the cycle of inflammatory activity and tissue injury that can contribute to worsening kidney function.
This differentiated mechanism may offer potential advantages compared with therapeutic strategies that focus on broadly suppressing the immune response. Maintaining an appropriate inflammatory balance is important because inflammation also plays a necessary role in normal immune defense and tissue repair.
Revelation believes that Gemini’s ability to regulate multiple inflammatory pathways could make it relevant to several conditions involving excessive or dysregulated inflammation.
Preclinical and Early Clinical Findings Support Further Development
The development strategy builds on findings generated through preclinical research and earlier clinical investigations of Gemini.
According to Revelation, preclinical studies demonstrated reductions in inflammation and kidney tissue damage following treatment with Gemini. These findings provided an initial scientific rationale for investigating the candidate’s potential role in conditions characterized by inflammatory injury.
In addition to the preclinical findings, Phase 1 clinical studies established evidence of biological activity and favorable tolerability.
The company also reported findings from studies involving patients with chronic kidney disease. In these patients, Gemini significantly reduced inflammatory activity and improved immune responsiveness.
Notably, the reported effects were observed for up to seven days, suggesting that the candidate may produce sustained biological activity following administration.
These findings are relevant to the company’s broader development strategy because they provide early evidence supporting Gemini’s ability to influence inflammatory and immune-related processes in humans.
However, additional clinical investigation will be necessary to establish whether these biological effects translate into meaningful improvements in kidney function and clinical outcomes among patients with acute kidney injury.
The planned Phase 2a study is expected to provide further information about the candidate’s safety, tolerability and potential efficacy in the targeted patient population.
Streamlined Phase 2a Clinical Study Planned for Early 2027
As part of its revised strategy, Revelation Biosciences plans to initiate a randomized, double-blind, sponsor-unblinded, placebo-controlled Phase 2a clinical study in patients with stage 2 or stage 3 acute kidney injury in early 2027.
The study is intended to evaluate Gemini’s safety and efficacy in this patient population while exploring clinical endpoints that could support subsequent development and regulatory discussions.
The company expects the trial to generate topline results in late 2027.
A randomized, placebo-controlled study design will allow investigators to compare outcomes between patients receiving Gemini and those receiving placebo. The double-blind design is intended to reduce potential bias in the assessment of treatment effects.
The sponsor-unblinded structure will allow the company to access designated study information while maintaining the planned blinding procedures for other relevant study personnel and participants.
An important objective of the study will be to investigate endpoints that could potentially support an approvable clinical development pathway. Revelation indicated that the selected endpoints will include measures previously discussed with the U.S. Food and Drug Administration (FDA).
Regulatory alignment regarding clinical endpoints is an important consideration in drug development because endpoints must adequately demonstrate treatment benefit and support the intended regulatory requirements.
By incorporating endpoints previously discussed with the FDA, Revelation aims to ensure that the Phase 2a study generates information that can help guide subsequent clinical development decisions.
The company expects the findings to provide a better understanding of Gemini’s potential therapeutic effects in patients with moderate-to-severe acute kidney injury.
Emory Healthcare and University of Alabama at Birmingham to Support Clinical Research
The planned Phase 2a study will be led by Laurence Busse, MD, at Emory Healthcare, with participation from Javier Neyra, MD, at the University of Alabama at Birmingham (UAB).
Emory Healthcare is the largest and most comprehensive academic health system in Georgia. Its involvement is expected to support the execution of the clinical investigation and the evaluation of Gemini in patients experiencing acute kidney injury.
The University of Alabama at Birmingham is also recognized as a major U.S. biomedical research and academic institution, with expertise across clinical medicine and scientific research.
The participation of investigators from these institutions is expected to support the study’s clinical execution and provide access to relevant expertise in kidney disease and critical care research.
The involvement of experienced clinical investigators is particularly important in acute kidney injury trials because patients can present with varying levels of disease severity, underlying medical conditions and treatment requirements.
The study will focus on patients with stage 2 or stage 3 AKI, allowing Revelation to investigate Gemini in a population with clinically significant kidney injury.
Through the collaboration, the company intends to generate clinical evidence that can inform future development strategies and potential partnership discussions.
Revised Development Strategy Reduces Expected Clinical Trial Costs
One of the most significant aspects of Revelation’s strategic shift is the substantial reduction in the anticipated cost of the next clinical study.
The company estimates that the streamlined Phase 2a trial will cost approximately $7 million, compared with approximately $60 million under its previous development approach.
EXPECTED PHASE 2A STUDY COST
$7M
Revised strategy
Expected study cost
$60M
Previous approach
Estimated study cost
This represents an approximately 88% reduction in the projected clinical study cost.
The lower-cost approach is intended to help the company preserve financial resources while continuing to advance Gemini through clinical development.
For a clinical-stage biotechnology company, managing development expenses and maintaining sufficient capital to reach important milestones are critical considerations.
By implementing a more focused Phase 2a study, Revelation aims to obtain relevant clinical data without undertaking the significantly more expensive development program previously contemplated.
The anticipated results in late 2027 could provide important evidence regarding Gemini’s safety and efficacy in AKI. These findings may also help the company determine the appropriate design and scope of subsequent clinical investigations.
Furthermore, the data are expected to strengthen Revelation’s ability to engage potential pharmaceutical partners by providing additional clinical information about the candidate’s therapeutic potential.
Revelation to Pursue Pharmaceutical Partnerships and Licensing Opportunities
In parallel with its clinical development plans, Revelation Biosciences intends to engage a business development firm to explore potential strategic transactions involving Gemini.
The company plans to evaluate licensing agreements, development partnerships and other strategic arrangements with biotechnology and pharmaceutical companies.
These opportunities could provide additional financial resources, development expertise and commercial infrastructure to support Gemini’s advancement.
Revelation believes the candidate’s differentiated multimodal mechanism of action, encouraging early clinical findings and substantial market opportunity in acute kidney injury could make it attractive to potential partners.
Pharmaceutical companies continue to evaluate innovative therapeutic candidates that address significant unmet medical needs, particularly in areas where existing treatment options are limited.
AKI represents an important potential development opportunity because of its high incidence among critically ill patients, the risk of progression to kidney failure and the absence of approved pharmacological therapies directly targeting the underlying inflammatory processes.
Through strategic collaborations, Revelation aims to explore opportunities to accelerate Gemini’s development and potentially expand its reach into additional therapeutic markets.
The company expects partnership discussions to benefit from the clinical evidence generated through the planned Phase 2a study.
Gemini Could Have Applications Beyond Acute Kidney Injury
Although the current clinical development strategy focuses on stage 2 and stage 3 acute kidney injury, Revelation believes Gemini’s mechanism of action could support applications across a broader range of inflammatory conditions.
The candidate’s ability to regulate multiple inflammatory pathways may be relevant to both acute and chronic diseases involving abnormal inflammatory responses.
One area of particular interest is chronic kidney disease (CKD), a progressive condition characterized by a gradual decline in kidney function.
The company’s previously reported findings in patients with CKD, including reductions in inflammatory activity and improvements in immune responsiveness lasting up to seven days, provide an early basis for investigating additional applications.
Beyond kidney-related disorders, Gemini’s multimodal mechanism could potentially be relevant to other diseases in which inflammation contributes to tissue damage and disease progression.
However, these additional applications remain potential development opportunities and would require appropriate clinical research to establish safety and therapeutic benefit in each targeted condition.
Revelation intends to explore partnership opportunities across multiple therapeutic areas where Gemini’s inflammatory pathway modulation may offer potential value.
The company will also evaluate opportunities to acquire or in-license complementary therapeutic assets that align with its broader focus on restoring inflammatory balance.
This approach could allow Revelation to expand its development portfolio while maintaining a strategic emphasis on innovative therapies targeting inflammation.
Financial Position and Future Development Priorities
As of September 30, 2026, Revelation Biosciences reported $9.1 million in cash and cash equivalents.
The company’s revised clinical development strategy is intended to align its available financial resources with the next major clinical milestone for Gemini.
With the planned Phase 2a study expected to cost approximately $7 million, Revelation is pursuing a more capital-efficient pathway while simultaneously exploring external partnership opportunities.
The company’s immediate priorities include preparing for the planned early 2027 clinical trial initiation, advancing discussions with potential strategic partners and generating clinical data to support future development decisions.
The expected topline results in late 2027 will represent an important milestone in determining Gemini’s potential role in treating acute kidney injury.
Overall, Revelation Biosciences’ strategic shift places greater emphasis on focused clinical development, reduced research expenses and external collaboration. By prioritizing a streamlined Phase 2a study and pursuing licensing and partnership opportunities, the company aims to advance Gemini while exploring its broader potential in inflammatory diseases.
For additional information about Revelation Biosciences and its clinical development programs, visit the company’s official website at www.RevBiosciences.com.
About Gemini
Gemini is Revelation Biosciences’ proprietary investigational therapeutic platform designed to rebalance the body’s innate immune response and address diseases associated with dysregulated inflammation.
Unlike approaches that broadly suppress inflammation, Gemini is designed to regulate excessive inflammatory activity while preserving the immune functions necessary for healing. Through its multimodal mechanism of action, Gemini activates the TRIF signaling pathway and other downstream biological processes to reduce pro-inflammatory signaling, stimulate inflammation-resolving responses and support tissue recovery.
Gemini is a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist. Gemini’s potential therapeutic activity has been demonstrated across multiple preclinical models, while Phase 1 clinical studies have demonstrated significant biological activity and modulation of inflammatory responses in humans.
Revelation’s lead development program, GEM-AKI, is focused on the treatment of acute kidney injury. The Company is also evaluating Gemini’s therapeutic potential in chronic kidney disease and other acute and chronic inflammatory conditions. See additional details here.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on developing innovative therapies to restore balance to the body’s inflammatory response. Through its proprietary Gemini therapeutic platform, Revelation is pursuing a differentiated approach to treating diseases driven by excessive or dysregulated inflammation.
The Company’s lead program targets acute kidney injury, a serious condition with significant unmet medical need and limited treatment options. Revelation believes Gemini’s multimodal mechanism of action has the potential to support improved healing and recovery across a broad range of acute and chronic inflammatory diseases.


